Evidence map›Paper›PMID 33589770›Full record

ArticleProstate cancer and prostatic diseases2021

Clinical significance of STEAP1 extracellular vesicles in prostate cancer.

Karan Khanna, Nikki Salmond, Kalan S Lynn, Hon S Leong, Karla C Williams

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Targeting STEAP1 as an anticancer strategy.Frontiers in oncology · 2023
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Karan KhannaFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.ORCID http://orcid.org/0000-0002-7695-6813
Nikki SalmondFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.
Kalan S LynnLawson Health Research Institute, London, ON, Canada.
Hon S LeongTranslational Urology Research Laboratory, Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. hon.leong@sri.utoronto.ca.
Karla C WilliamsFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada. karla.williams@ubc.ca.ORCID http://orcid.org/0000-0003-2954-2869
University of British Columbia · CALawson Health Research Institute · CASunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtracellular vesicles (EVs) are cell-derived lipid bilayer enclosed structures shed from the plasma membrane by all cell types. Evidence of EV presence in biological fluids has led to considerable efforts focused on identifying their cargo and determining their utility as a non-invasive diagnostic platform for cancer. In this study, we identify circulating STEAP1 (six-transmembrane epithelial antigen of the prostate 1)-positive EVs in the plasma of healthy males and prostate cancer patients and evaluate its diagnostic and prognostic significance.

methodsSTEAP1 was identified on EVs in prostate cancer patient plasma. EVs were validated using electron microscopy, Western blot, nanoparticle tracking analysis, and nanoscale flow cytometry. STEAP1-positive EVs were quantified for 121 males with prostate cancer and 55 healthy age-matched control males. An evaluation of STEAP1 in prostate cancer tissue was also performed using established prostate cancer cohort data (TCGA, MSKCC, and SU2C/PCF Dream Team).

resultsEvaluation of STEAP1-positive EVs by nanoscale flow cytometry identified a significant increase in prostate cancer patient plasma compared to healthy males. However, no association was found between total STEAP1 EV levels and disease recurrence or overall survival. Cohort data from prostate cancer tissue also found STEAP1 to be elevated in prostate cancer while no significant association with recurrence or overall survival was identified.

conclusionsSTEAP1 is known to be enriched on the cells of the prostate with potential clinical significance in prostate cancer. Our results identify and quantitate STEAP1-positive EVs in plasma and provide rationale for a STEAP1 EV-based liquid biopsy as a diagnostic strategy in prostate cancer.

Indexed as

AgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCase-Control StudiesExtracellular VesiclesFollow-Up StudiesHumansLiquid BiopsyMaleMiddle AgedNeoplasm Recurrence, LocalOxidoreductasesPrognosisProstatic NeoplasmsAntigens, NeoplasmBiomarkers, TumorOxidoreductasesSTEAP1 protein, human

Identifiers

PMID33589770
PMCPMC8384631
OpenAlexW3132823884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.